Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade

Group 1 - BioCryst Pharmaceuticals (BCRX) closed at $10.59, with a 26.2$16.50 indicating a 55.8% upside potential [1] - The average of 12 short-term price targets ranges from a low of $11 to a high of$30, with a standard deviation of $5.32, suggesting variability in analyst estimates [2] - Analysts show strong agreement on BCRX's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 366.9% over the past month, with six estimates revised higher and no negative revisions [12] - BCRX holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While consensus price targets may not be reliable for predicting stock gains, they can indicate potential price movement direction [13]